Corrigendum to Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver: [Eur.J.Pharmacol.789(2016)60-67] (S0014299916304435) (10.1016/j.ejphar.2016.07.012));Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver

European Journal of Pharmacology

Volumn 789, Issue , 2016, Pages 60-67

  Lu, Chieh Hua ^a,b   Hung, Yi Jen ^a   Hsieh, Po Shiuan ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Adipose tissue inflammation; COX 2 inhibitor; Fatty liver; Insulin resistance; Metformin; Obesity

Indexed keywords

CELECOXIB; GLUCOSE; LEPTIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ADIPOCYTOKINE; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; TUMOR NECROSIS FACTOR;

ADIPOCYTE; ADIPOSE TISSUE INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL INFILTRATION; CELL SIZE; CONTROLLED STUDY; DISORDERS OF LIPID METABOLISM; DRUG EFFICACY; DRUG RESPONSE; FATTY LIVER; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; MALE; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; ADIPOSE TISSUE; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; DRUG POTENTIATION; EATING; ENZYME ACTIVATION; GLUCOSE TOLERANCE TEST; LIPID METABOLISM; LIVER; MACROPHAGE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CELECOXIB; CELL SIZE; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; EATING; ENZYME ACTIVATION; FATTY LIVER; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MACROPHAGES; MALE; METFORMIN; OBESITY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978716336     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.12.046     Document Type: Erratum

References (38)

1. American Diabetes, A., (7) Approaches to glycemic treatment. Diabetes Care 38:Suppl (2015), S41–S48.
2. Arner, P., Langin, D., Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol. Metab.: TEM 25 (2014), 255–262.
3. Audia, P., Feinfeld, D.A., Dubrow, A., Winchester, J.F., Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction. Clin. Toxicol. 46 (2008), 164–166.
4. Boyle, J.G., Logan, P.J., Jones, G.C., Small, M., Sattar, N., Connell, J.M., Cleland, S.J., Salt, I.P., AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia 54 (2011), 1799–1809.
5. Chan, A.L., Celecoxib-induced deep-vein thrombosis. Ann. Pharmacother., 39, 2005, 1138.
6. Chawla, A., Nguyen, K.D., Goh, Y.P., Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11 (2011), 738–749.
7. Djouder, N., Tuerk, R.D., Suter, M., Salvioni, P., Thali, R.F., Scholz, R., Vaahtomeri, K., Auchli, Y., Rechsteiner, H., Brunisholz, R.A., Viollet, B., Makela, T.P., Wallimann, T., Neumann, D., Krek, W., PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J. 29 (2010), 469–481.
8. Flier, J.S., Obesity wars: molecular progress confronts an expanding epidemic. Cell 116 (2004), 337–350.
9. Fullerton, M.D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.P., O'Neill, H.M., Ford, R.J., Palanivel, R., O'Brien, M., Hardie, D.G., Macaulay, S.L., Schertzer, J.D., Dyck, J.R., van Denderen, B.J., Kemp, B.E., Steinberg, G.R., Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19 (2013), 1649–1654.
10. Galic, S., Fullerton, M.D., Schertzer, J.D., Sikkema, S., Marcinko, K., Walkley, C.R., Izon, D., Honeyman, J., Chen, Z.P., van Denderen, B.J., Kemp, B.E., Steinberg, G.R., Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Investig. 121 (2011), 4903–4915.
11. Gauthier, M.S., Miyoshi, H., Souza, S.C., Cacicedo, J.M., Saha, A.K., Greenberg, A.S., Ruderman, N.B., AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J. Biol. Chem. 283 (2008), 16514–16524.
12. Ghoshal, S., Trivedi, D.B., Graf, G.A., Loftin, C.D., Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. J. Biol. Chem. 286 (2011), 889–898.
13. Gross, J.L., Kramer, C.K., Leitao, C.B., Hawkins, N., Viana, L.V., Schaan, B.D., Pinto, L.C., Rodrigues, T.C., Azevedo, M.J., Diabetes, Endocrinology Meta-analysis, G., 2011. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Annals of Internal Medicine. Vol. 154, pp. 672–679.
14. Guilherme, A., Virbasius, J.V., Puri, V., Czech, M.P., Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9 (2008), 367–377.
15. Howe, L.R., Subbaramaiah, K., Hudis, C.A., Dannenberg, A.J., Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin. Cancer Res: Off. J. Am. Assoc. Cancer Res. 19 (2013), 6074–6083.
16. Hsieh, P.S., Attenuation of insulin-mediated pressor effect and nitric oxide release in rats with fructose-induced insulin resistance. Am. J. Hypertens. 17 (2004), 707–711.
17. Hsieh, P.S., Lu, K.C., Chiang, C.F., Chen, C.H., Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats. Eur. J. Clin. Investig. 40 (2010), 164–171.
18. Hsieh, P.S., Jin, J.S., Chiang, C.F., Chan, P.C., Chen, C.H., Shih, K.C., COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity 17 (2009), 1150–1157.
19. Hsieh, P.S., Tsai, H.C., Kuo, C.H., Chan, J.Y., Shyu, J.F., Cheng, W.T., Liu, T.T., Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats. Eur. J. Clin. Investig. 38 (2008), 812–819.
20. Ji, L.N., Pan, C.Y., Lu, J.M., Li, H., Li, Q., Li, Q.F., Peng, Y.D., Tian, H.M., Yao, C., Zhao, Z.G., Zhang, R.Y., Wang, X.L., Wang, L., Group, V.S., Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovasc. Diabetol., 12, 2013, 118.
21. Kang, D., Yun, J.S., Ko, S.H., Lim, T.S., Ahn, Y.B., Park, Y.M., Ko, S.H., Higher prevalence of metformin-induced vitamin B12 deficiency in sulfonylurea combination compared with insulin combination in patients with type 2 diabetes: a cross-sectional study. PloS One, 9, 2014, e109878.
22. Konheim, Y.L., Wolford, J.K., Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum. Genet. 113 (2003), 377–381.
23. Kopelman, P.G., Obesity as a medical problem. Nature 404 (2000), 635–643.
24. Lang, F., Gulbins, E., Lang, P.A., Zappulla, D., Foller, M., Ceramide in suicidal death of erythrocytes. Cellular physiology and biochemistry. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 26 (2010), 21–28.
25. Leclercq, I.A., Farrell, G.C., Sempoux, C., dela Pena, A., Horsmans, Y., Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41 (2004), 926–934.
26. Lupescu, A., Bissinger, R., Jilani, K., Lang, F., Triggering of suicidal erythrocyte death by celecoxib. Toxins 5 (2013), 1543–1554.
27. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
28. Musso, G., Cassader, M., Rosina, F., Gambino, R., Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55 (2012), 885–904.
29. Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., Zinman, B., American Diabetes, A., European Association for the Study of, D, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52 (2009), 17–30.
30. Park, M.H., Kinra, S., Ward, K.J., White, B., Viner, R.M., Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 32 (2009), 1743–1745.
31. Shaw, R.J., Metformin trims fats to restore insulin sensitivity. Nat. Med. 19 (2013), 1570–1572.
32. Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J. Clin. Investig. 116 (2006), 1793–1801.
33. Stephenne, X., Foretz, M., Taleux, N., van der Zon, G.C., Sokal, E., Hue, L., Viollet, B., Guigas, B., Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54 (2011), 3101–3110.
34. Subbaramaiah, K., Howe, L.R., Bhardwaj, P., Du, B., Gravaghi, C., Yantiss, R.K., Zhou, X.K., Blaho, V.A., Hla, T., Yang, P., Kopelovich, L., Hudis, C.A., Dannenberg, A.J., Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. 4 (2011), 329–346.
35. Wellen, K.E., Hotamisligil, G.S., Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112 (2003), 1785–1788.
36. Winer, S., Winer, D.A., The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance. Immunol. Cell Biol. 90 (2012), 755–762.
37. Yu, J., Ip, E., Dela Pena, A., Hou, J.Y., Sesha, J., Pera, N., Hall, P., Kirsch, R., Leclercq, I., Farrell, G.C., COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 43 (2006), 826–836.
38. Zappulla, D., Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2increases?. J. Cardiometab. Syndr. 3 (2008), 30–34.